US › Healthcare

Kyverna Therapeutics, Inc. Common Stock (KYTX)

US · Healthcare · Biotechnology

$7.78+3.60%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$0
Net profit
$-39.7M
Profit YoY
+11.0%
EPS
$-0.66
EPS estimate
$-0.73

EPS came in at -0.66 against a street estimate of -0.73 — a beat of 10.1%.

Key statistics

Market cap
$443.8M
Forward P/E
0.0
P/B
2.27
Book value
$3.23
EPS (TTM)
$-3.27
52-week high
$13.67
52-week low
$2.80
50-day MA
$8.15
200-day MA
$8.27
Beta
1.88

Analyst view

Analysts rate Kyverna Therapeutics, Inc. Common Stock a strong buy (6 buy, 0 hold, 0 sell out of 6) with an average price target of $30.40.

Shareholding

Insiders
7.10%
Institutions
75.40%

Largest institutional holders

FundStake
GordonMD Global Investments LP6.98%
Bain Capital Life Sciences Investors, LLC5.12%
AIGH Capital Management, LLC3.29%
Deerfield Management Co3.29%
Vanguard Capital Management, LLC2.93%
Vanguard Group Inc2.93%
T. Rowe Price Associates, Inc.2.56%
Balyasny Asset Management LLC1.85%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Kyverna Therapeutics, Inc. Common Stock — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.